Norges Bank Neurocrine Biosciences Inc Transaction History

Norges Bank

$772 Billion
Q2 2025

A detailed history of Norges Bank transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Norges Bank holds 972,856 shares of NBIX stock, worth $125 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

972,856

Holding current value

$125 Million

% of portfolio

0.02%

51 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$87.54 - $128.18 $85.2 Million - $125 Million	972,856 New	972,856 $122 Million
Q4 2024 Feb 12, 2025	BUY	$111.62 - $139.44 $36.3 Million - $45.4 Million	325,295 New	325,295 $44.4 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $58.8 Million - $64.4 Million	449,565 New	449,565 $61.9 Million
Q1 2024 May 14, 2025	BUY	$130.4 - $143.74 $55.4 Million - $61.1 Million	425,216 New	425,216 $58.6 Million
Q4 2023 Feb 09, 2024	BUY	$106.07 - $132.76 $28.8 Million - $36 Million	271,182 New	271,182 $35.7 Million
Q3 2023 Nov 13, 2024	BUY	$94.02 - $117.1 $7.51 Million - $9.36 Million	79,905 New	79,905 $8.99 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $82.1 Million - $102 Million	-873,673 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$89.53 - $104.87 $35.4 Million - $41.4 Million	-395,238 Reduced 87.92%	54,327 $5.12 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $76.5 Million - $89.7 Million	-854,942 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$94.11 - $123.02 $74.9 Million - $97.9 Million	795,410 New	795,410 $80.5 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $99.9 Million - $119 Million	935,915 New	935,915 $112 Million
Q3 2022 Nov 13, 2023	BUY	$92.03 - $107.81 $80.4 Million - $94.2 Million	873,673 New	873,673 $92.8 Million
Q2 2022 Aug 14, 2023	BUY	$75.79 - $100.07 $64.8 Million - $85.6 Million	854,942 New	854,942 $83.3 Million
Q1 2022 May 12, 2023	SELL	$72.45 - $94.81 $7.6 Million - $9.94 Million	-104,856 Reduced 11.2%	831,059 $77.9 Million
Q1 2022 May 09, 2022	SELL	$72.45 - $94.81 $55.7 Million - $72.9 Million	-768,416 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$79.65 - $106.22 $61.2 Million - $81.6 Million	768,416 New	768,416 $65.4 Million
Q3 2021 Nov 14, 2022	BUY	$86.18 - $99.03 $65.9 Million - $75.7 Million	764,419 New	764,419 $73.3 Million
Q3 2021 Nov 05, 2021	SELL	$86.18 - $99.03 $63.2 Million - $72.6 Million	-733,202 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$89.43 - $102.27 $65.6 Million - $75 Million	733,202 New	733,202 $71.4 Million
Q2 2021 Aug 10, 2021	SELL	$89.43 - $102.27 $61.3 Million - $70.1 Million	-685,602 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$87.57 - $119.4 $60 Million - $81.9 Million	685,602 New	685,602 $66.7 Million
Q1 2021 May 07, 2021	SELL	$87.57 - $119.4 $61.9 Million - $84.5 Million	-707,402 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$86.91 - $108.33 $61.5 Million - $76.6 Million	707,402 New	707,402 $67.8 Million
Q4 2020 Feb 10, 2021	SELL	$86.91 - $108.33 $64.3 Million - $80.1 Million	-739,351 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$96.16 - $135.15 $71.1 Million - $99.9 Million	739,351 New	739,351 $71.1 Million
Q3 2020 Nov 10, 2020	SELL	$96.16 - $135.15 $72.4 Million - $102 Million	-752,551 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$85.09 - $130.36 $64 Million - $98.1 Million	752,551 New	752,551 $91.8 Million
Q2 2020 Aug 07, 2020	SELL	$85.09 - $130.36 $67.3 Million - $103 Million	-790,835 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$75.11 - $113.76 $59.4 Million - $90 Million	790,835 New	790,835 $68.4 Million
Q1 2020 May 08, 2020	SELL	$75.11 - $113.76 $59 Million - $89.4 Million	-785,914 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$86.8 - $118.57 $68.2 Million - $93.2 Million	785,914 New	785,914 $84.5 Million
Q4 2019 Feb 12, 2020	SELL	$86.8 - $118.57 $74.4 Million - $102 Million	-856,611 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$83.82 - $101.5 $71.8 Million - $86.9 Million	856,611 New	856,611 $77.2 Million
Q3 2019 Nov 08, 2019	SELL	$83.82 - $101.5 $71.8 Million - $86.9 Million	-856,611 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$72.24 - $91.27 $61.9 Million - $78.2 Million	856,611 New	856,611 $72.3 Million
Q2 2019 Aug 09, 2019	SELL	$72.24 - $91.27 $61.9 Million - $78.2 Million	-856,611 Closed	0 $0
Q4 2018 Mar 04, 2019	BUY	$68.32 - $124.36 $58.5 Million - $107 Million	856,611 New	856,611 $61.2 Million
Q4 2018 Feb 08, 2019	SELL	$68.32 - $124.36 $58.5 Million - $107 Million	-856,611 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$98.88 - $125.85 $84.7 Million - $108 Million	856,611 New	856,611 $105 Million
Q3 2018 Nov 09, 2018	SELL	$98.88 - $125.85 $84.7 Million - $108 Million	-856,611 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$75.3 - $105.99 $64.5 Million - $90.8 Million	856,611 New	856,611 $84.2 Million
Q2 2018 Jul 23, 2018	SELL	$75.3 - $105.99 $66 Million - $92.9 Million	-876,268 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$75.88 - $92.43 $66.5 Million - $81 Million	876,268 New	876,268 $72.7 Million
Q1 2018 May 09, 2018	SELL	$75.88 - $92.43 $66.5 Million - $81 Million	-876,268 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$58.53 - $77.59 $51.3 Million - $68 Million	876,268 New	876,268 $68 Million
Q4 2017 Feb 09, 2018	SELL	$58.53 - $77.59 $51.3 Million - $68 Million	-876,268 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$47.97 - $61.28 $42 Million - $53.7 Million	876,268 New	876,268 $53.7 Million
Q3 2017 Nov 07, 2017	SELL	$47.97 - $61.28 $42 Million - $53.7 Million	-876,268 Closed	0 $0
Q2 2017 Jul 24, 2018	BUY	N/A	80,974 Added 10.18%	876,268 $40.3 Million
Q1 2017 May 11, 2018	SELL	N/A	-103,360 Reduced 11.5%	795,294 $34.4 Million
Q3 2016 Nov 13, 2017	BUY	N/A	898,654	898,654 $0

Others Institutions Holding NBIX

# of Institutions

656

Shares Held

101M

Call Options Held

282K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account